Prelude Therapeutics (PRLD) Profit After Tax Growth (1y) (2020 - 2026)

Prelude Therapeutics (PRLD) Profit After Tax Growth (1y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 0.26%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 17,802.13%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 59.59%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -107.76%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 101.22%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Prelude Therapeutics 322.24 Mn 177.64 Mn - 67.50%

Historic Data

Download Data
DateValue
Mar 31, 2026 67.50%
Dec 31, 2025 43.21%
Sep 30, 2025 38.88%
Jun 30, 2025 10.10%
Mar 31, 2025 -2.15%
Dec 31, 2024 10.32%
Sep 30, 2024 -5.43%
Jun 30, 2024 -14.16%
Mar 31, 2024 -13.40%
Dec 31, 2023 -15.29%
Sep 30, 2023 -1.93%
Jun 30, 2023 -11.17%
Mar 31, 2023 5.93%
Dec 31, 2022 14.83%
Sep 30, 2022 2.71%
Jun 30, 2022 -1.89%
Mar 31, 2022 -38.33%
Dec 31, 2021 -70.61%
Sep 30, 2021 -84.15%
Jun 30, 2021 -135.49%